RVL PHARMA PLC (RVLP)
(Delayed Data from NSDQ)
$NA USD
0 (0.00%)
Updated Dec 31, 1969 06:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for RVL Pharmaceuticals PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 45 | 40 | 114 | 96 |
Receivables | NA | 3 | 2 | 26 | 44 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 1 | 1 | 18 | 21 |
Other Current Assets | NA | 9 | 16 | 15 | 12 |
Total Current Assets | NA | 57 | 59 | 173 | 173 |
Net Property & Equipment | NA | 1 | 1 | 28 | 30 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 70 | 83 | 167 | 255 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 1 |
Total Assets | NA | 129 | 145 | 371 | 463 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 4 | 7 | 9 |
Current Portion Long-Term Debt | NA | 1 | 2 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 15 | 13 | 48 | 65 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 20 | 20 | 56 | 76 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 2 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 56 | 44 | 220 | 268 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 2 | 3 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 77 | 68 | 277 | 349 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 619 | 592 | 548 | 489 |
Retained Earnings | NA | -569 | -518 | -453 | -373 |
Other Equity | NA | 0 | 2 | -2 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 51 | 77 | 94 | 115 |
Total Liabilities & Shareholder's Equity | NA | 129 | 145 | 371 | 463 |
Total Common Equity | 0 | 51 | 77 | 94 | 115 |
Shares Outstanding | 111.40 | 99.20 | 83.30 | 62.50 | 51.50 |
Book Value Per Share | 0.00 | 0.52 | 0.92 | 1.50 | 2.23 |
Fiscal Year End for RVL Pharmaceuticals PLC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | 19 |
Receivables | NA | NA | NA | NA | 2 |
Notes Receivable | NA | NA | NA | NA | 0 |
Inventories | NA | NA | NA | NA | 1 |
Other Current Assets | NA | NA | NA | NA | 3 |
Total Current Assets | NA | NA | NA | NA | 26 |
Net Property & Equipment | NA | NA | NA | NA | 3 |
Investments & Advances | NA | NA | NA | NA | 0 |
Other Non-Current Assets | NA | NA | NA | NA | 0 |
Deferred Charges | NA | NA | NA | NA | 0 |
Intangibles | NA | NA | NA | NA | 56 |
Deposits & Other Assets | NA | NA | NA | NA | 0 |
Total Assets | NA | NA | NA | NA | 85 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | 0 |
Accounts Payable | NA | NA | NA | NA | 3 |
Current Portion Long-Term Debt | NA | NA | NA | NA | 58 |
Current Portion Capital Leases | NA | NA | NA | NA | 0 |
Accrued Expenses | NA | NA | NA | NA | 8 |
Income Taxes Payable | NA | NA | NA | NA | 0 |
Other Current Liabilities | NA | NA | NA | NA | 0 |
Total Current Liabilities | NA | NA | NA | NA | 68 |
Mortgages | NA | NA | NA | NA | 0 |
Deferred Taxes/Income | NA | NA | NA | NA | 0 |
Convertible Debt | NA | NA | NA | NA | 0 |
Long-Term Debt | NA | NA | NA | NA | 0 |
Non-Current Capital Leases | NA | NA | NA | NA | 0 |
Other Non-Current Liabilities | NA | NA | NA | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
Total Liabilities | NA | NA | NA | NA | 69 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | 0 |
Common Stock (Par) | NA | NA | NA | NA | 1 |
Capital Surplus | NA | NA | NA | NA | 620 |
Retained Earnings | NA | NA | NA | NA | -605 |
Other Equity | NA | NA | NA | NA | 0 |
Treasury Stock | NA | NA | NA | NA | 0 |
Total Shareholder's Equity | NA | NA | NA | NA | 16 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | 85 |
Total Common Equity | 0 | 0 | 0 | 0 | 16 |
Shares Outstanding | 111.40 | 111.40 | 111.40 | 111.40 | 99.30 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 |